ArticleTherapeutics and clinical risk management2021
High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy.
Article in Therapeutics and clinical risk management, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Development and Validation of a Neutrophil Percentage-to-Albumin Ratio-Based Nomogram for Predicting Overall Survival in Locally Advanced Nasopharyngeal Carcinoma.Journal of inflammation research · 2026Article
- Neutrophil-albumin ratio and multi-phase computed tomography for lymph node metastasis in pancreatic cancer.World journal of gastrointestinal oncology · 2025Article
- Prechemoradiotherapy number of natural teeth as a prognostic factor in patients with locally advanced nasopharyngeal cancer: A retrospective observational study.The Journal of international medical research · 2025Observational
- Preoperative Platelet/Albumin Ratio Predicts Morbidity and Mortality in Patients with Retroperitoneal Liposarcoma.Indian journal of surgical oncology · 2025Article
- Platelet-to-albumin ratio is an independent predictor for ventricular aneurysm formation in ST segment elevation myocardial infarction.Coronary artery disease · 2025Article
- The predictive value of the serum creatinine-to-albumin ratio (sCAR) and lactate dehydrogenase-to-albumin ratio (LAR) in sepsis-related persistent severe acute kidney injury.European journal of medical research · 2025Article
- High platelet-to-albumin ratio is associated with 30-day mortality in critically ill patients.European journal of medical research · 2024Article
- The Prediction of Radiation-Induced Trismus by the Apparent Diffusion Coefficient Values of Masseter Muscles before Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinomas.Diagnostics (Basel, Switzerland) · 2024Article
- Are Platelet-Related Parameters Prognostic Predictors of Renal and Cardiovascular Outcomes in IgA Nephropathy?Journal of clinical medicine · 2024Article
- Platelet-to-albumin ratio and radiation-induced lymphopenia-prognostic biomarker for carcinoma esophagus.Journal of the Egyptian National Cancer Institute · 2024Article
- A novel nomogram for predicting mortality risk in young and middle-aged patients undergoing maintenance hemodialysis: a retrospective study.Frontiers in medicine · 2024Article
- Predicting Teeth Extraction after Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Cancer Patients Using the Novel GLUCAR Index.Diagnostics (Basel, Switzerland) · 2023Article
- Development and validation of platelet-to-albumin ratio as a clinical predictor for diffuse large B-cell lymphoma.Frontiers in oncology · 2023Article
- Predictive Value of Platelet-to-Albumin Ratio (PAR) for the Cardiac-Associated Acute Kidney Injury and Prognosis of Patients in the Intensive Care Unit.International journal of general medicine · 2022Article
- Platelet-to-Albumin Ratio: A Novel IgA Nephropathy Prognosis Predictor.Frontiers in immunology · 2022Article
- Predictive Value of the Platelet-to-Albumin Ratio (PAR) on the Risk of Death at Admission in Patients Suffering from Severe Fever with Thrombocytopenia Syndrome.Journal of inflammation research · 2021Article
- Clinical Impact of Platelet-to-albumin Ratio on Esophageal Cancer Patients Who Receive Curative Treatment.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn a lack of similar research, we assessed the prognostic utility of pretreatment platelet-to-albumin ratio (PAR) in locally advanced nasopharyngeal carcinoma (LANPC) patients managed with concurrent chemoradiotherapy (CCRT). PATIENTS AND
methodsPresent retrospective analysis included a sum of 128 consecutively treated LANPC patients who underwent cisplatinum-based radical CCRT. Availability of an ideal pretreatment PAR cutoff that may stratify the study population into two cohorts with significantly distinct survival outcomes was sought by utilizing the receiver operating characteristic (ROC) curve analysis. The primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS), respectively.
resultsA rounded 5.2 [area under the curve (AUC): 68.9%; sensitivity: 67.4%; and specificity: 65.2%] value was identified as the ideal PAR cutoff that grouped patients into two gatherings [PAR≥5.2 (N=60) versus <5.2 (N=68)]. The median follow-up duration was 86.4 months (range: 9-147). Kaplan-Meier comparisons between the two PAR groups revealed significantly diminished median PFS (69.4 versus 106.8 months for PAR<5.2; P< 0.012) and OS (88.3 versus not reached yet for PAR<5.2; P= 0.023) for the PAR ≥ 5.2 group. The results of multivariate analyses affirmed the pretreatment PAR≥5.2 as an independent prognostic factor that indicates diminished PFS (P= 0.016) and OS (P= 0.019) together with the respective N
conclusionThe results of the current retrospective analysis provided a robust and independent adverse prognostic value for pretreatment PAR ≥ 5.2 in terms of median and long-term PFS and OS outcomes in LA-NPC patients this patient group treated with conclusive CCRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.